 Connection
Toan Ong to Influenza Vaccines
This is a "connection" page, showing publications Toan Ong has written about Influenza Vaccines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.978 |
|
|
|
-
Azziz-Baumgartner E, Budd A, Lee JS, Iuliano AD, Ellington SR, Levine MZ, Zheng XY, Gubareva L, Adams K, DeCuir J, Bozio CH, Reed C, Kirby MK, Rambo-Martin B, Jones JM, Biggerstaff M, Garg S, Davis CT, Shimabukuro TT, Burns E, Kondor R, Olsen SJ, Dugan VG, Irving SA, Naleway AL, Dascomb K, Sheffield T, DeSilva MB, Tartof SY, Sy LS, Klein NP, Zerbo O, Grannis SJ, Dixon BE, Stockwell MS, Stephens AB, Ong TC, Barron MA, Ball SW, Weber ZA, Reeves EL, Ray CS. Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Netw Open. 2026 Jun 01; 9(6):e2618581.
Score: 0.171
-
Maloney P, Reeves EL, Wielgosz K, Price AM, Natarajan K, DeSilva MB, Dascomb K, Klein NP, Tartof SY, Irving SA, Grannis SJ, Ong TC, Weber ZA, Schuster JE, Zerr DM, Michaels MG, Boom JA, Halasa NB, Staat MA, Weinberg GA, House SL, Saade EA, Geffel KM, Gaglani M, Wernli KJ, Murugan V, Martin ET, Bontrager NAB, Kirby MK, Payne AB, Dawood FS, Tannis A, Moline HL, Zhao SK, Adams K, DeCuir J, Olson SM, Chung JR, Lewis N, Flannery B, Reed C, Garg S, Ellington S. Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026. MMWR Morb Mortal Wkly Rep. 2026 Mar 12; 75(9):116-123.
Score: 0.168
-
Tenforde MW, Reeves EL, Weber ZA, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Yang DH, Grannis SJ, Irving SA, Ong TC, Link-Gelles R, Salas SB, Sy LS, Lewin B, Contreras R, Zerbo O, Fireman B, Hansen J, Timbol J, Sheffield T, Bride D, Arndorfer J, VanOtterloo J, McEvoy CE, Akinsete OO, Essien IJ, Dixon BE, Rogerson C, Fadel WF, Duszynski T, Naleway AL, Barron MA, Rao S, Mayer D, Chavez C, Ball SW, Payne AB, Ray C, Dickerson M, Neelam V, Adams K, Flannery B, DeCuir J, Garg S. Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023-2024 Season, United States. Clin Infect Dis. 2025 Oct 06; 81(3):667-678.
Score: 0.163
-
Reeves EL, Dascomb K, Irving SA, Klein NP, Tartof SY, Grannis SJ, Ong TC, Ball SW, Vazquez-Benitez G, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Naleway AL, Koppolu P, Zerbo O, Jacobson KB, Fireman BH, Hansen JR, Block L, Salas SB, Bezi C, Sy LS, Reyes IAC, Dixon BE, Fadel WF, Rogerson C, Duszynski T, Mayer D, Chavez C, Barron MA, Weber ZA, Yang DH, Cheung A, Payne AB, Link-Gelles R, Adams K, Neelam V, DeSilva MB, Natarajan K, Tenforde MW, DeCuir J, Ellington S, Olson SM. Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age. Vaccine. 2025 Aug 30; 62:127483.
Score: 0.161
-
Frutos AM, Cleary S, Reeves EL, Ahmad HM, Price AM, Self WH, Zhu Y, Safdar B, Peltan ID, Gibbs KW, Exline MC, Lauring AS, Ball SW, DeSilva M, Tartof SY, Dascomb K, Irving SA, Klein NP, Dixon BE, Ong TC, Vaughn IA, House SL, Faryar KA, Nowalk MP, Gaglani M, Wernli KJ, Murugan V, Williams OL, Selvarangan R, Weinberg GA, Staat MA, Halasa NB, Sahni LC, Michaels MG, Englund JA, Kirby MK, Surie D, Dawood FS, Clopper BR, Moline HL, Link-Gelles R, Payne AB, Harker E, Wielgosz K, Weber ZA, Yang DH, Lewis NM, DeCuir J, Olson SM, Chung JR, Flannery B, Grohskopf LA, Reed C, Garg S, Ellington S. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):83-90.
Score: 0.157
-
Tenforde MW, Weber ZA, Yang DH, DeSilva MB, Dascomb K, Irving SA, Naleway AL, Gaglani M, Fireman B, Lewis N, Zerbo O, Goddard K, Timbol J, Hansen JR, Grisel N, Arndorfer J, McEvoy CE, Essien IJ, Rao S, Grannis SJ, Kharbanda AB, Natarajan K, Ong TC, Embi PJ, Ball SW, Dunne MM, Kirshner L, Wiegand RE, Dickerson M, Patel P, Ray C, Flannery B, Garg S, Adams K, Klein NP. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
Score: 0.150
-
Link-Gelles R, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Weber ZA, Fleming-Dutra KE, McEvoy CE, Akinsete O, Bride D, Sheffield T, Naleway AL, Zerbo O, Fireman B, Hansen J, Goddard K, Dixon BE, Rogerson C, Fadel WF, Duszynski T, Rao S, Barron MA, Reese SE, Ball SW, Dunne MM, Natarajan K, Okwuazi E, Shah AB, Wiegand R, Tenforde MW, Payne AB. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
Score: 0.147
-
Adams K, Weber ZA, Yang DH, Klein NP, DeSilva MB, Dascomb K, Irving SA, Naleway AL, Rao S, Gaglani M, Flannery B, Garg S, Kharbanda AB, Grannis SJ, Ong TC, Embi PJ, Natarajan K, Fireman B, Zerbo O, Goddard K, Timbol J, Hansen JR, Grisel N, Arndorfer J, Ball SW, Dunne MM, Kirshner L, Chung JR, Tenforde MW. Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network. Clin Infect Dis. 2024 03 20; 78(3):746-755.
Score: 0.147
-
Payne AB, Ciesla AA, Rowley EAK, Weber ZA, Reese SE, Ong TC, Vazquez-Benitez G, Naleway AL, Klein NP, Embi PJ, Grannis SJ, Kharbanda AB, Gaglani M, Tenforde MW, Link-Gelles R. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. Vaccine. 2023 12 12; 41(51):7581-7586.
Score: 0.143
-
Tenforde MW, Weber ZA, DeSilva MB, Stenehjem E, Yang DH, Fireman B, Gaglani M, Kojima N, Irving SA, Rao S, Grannis SJ, Naleway AL, Kirshner L, Kharbanda AB, Dascomb K, Lewis N, Dalton AF, Ball SW, Natarajan K, Ong TC, Hartmann E, Embi PJ, McEvoy CE, Grisel N, Zerbo O, Dunne MM, Arndorfer J, Goddard K, Dickerson M, Patel P, Timbol J, Griggs EP, Hansen J, Thompson MG, Flannery B, Klein NP. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network. J Infect Dis. 2023 07 14; 228(2):185-195.
Score: 0.140
-
Schrag SJ, Verani JR, Dixon BE, Page JM, Butterfield KA, Gaglani M, Vazquez-Benitez G, Zerbo O, Natarajan K, Ong TC, Lazariu V, Rao S, Beaver R, Ellington SR, Klein NP, Irving SA, Grannis SJ, Kiduko S, Barron MA, Midturi J, Dickerson M, Lewis N, Stockwell MS, Stenehjem E, Fadel WF, Link-Gelles R, Murthy K, Goddard K, Grisel N, Valvi NR, Fireman B, Arndorfer J, Konatham D, Ball S, Thompson MG, Naleway AL. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
Score: 0.132
-
Link-Gelles R, Levy ME, Gaglani M, Irving SA, Stockwell M, Dascomb K, DeSilva MB, Reese SE, Liao IC, Ong TC, Grannis SJ, McEvoy C, Patel P, Klein NP, Hartmann E, Stenehjem E, Natarajan K, Naleway AL, Murthy K, Rao S, Dixon BE, Kharbanda AB, Akinseye A, Dickerson M, Lewis N, Grisel N, Han J, Barron MA, Fadel WF, Dunne MM, Goddard K, Arndorfer J, Konatham D, Valvi NR, Currey JC, Fireman B, Raiyani C, Zerbo O, Sloan-Aagard C, Ball SW, Thompson MG, Tenforde MW. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
Score: 0.131
-
Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, Klein NP, DeSilva MB, Ong TC, Grannis SJ, Stenehjem E, Link-Gelles R, Rowley EA, Naleway AL, Han J, Raiyani C, Benitez GV, Rao S, Lewis N, Fadel WF, Grisel N, Griggs EP, Dunne MM, Stockwell MS, Mamawala M, McEvoy C, Barron MA, Goddard K, Valvi NR, Arndorfer J, Patel P, Mitchell PK, Smith M, Kharbanda AB, Fireman B, Embi PJ, Dickerson M, Davis JM, Zerbo O, Dalton AF, Wondimu MH, Azziz-Baumgartner E, Bozio CH, Reynolds S, Ferdinands J, Williams J, Schrag SJ, Verani JR, Ball S, Thompson MG, Dixon BE. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
Score: 0.128
-
Frutos AM, Tenforde MW, Sundaresan D, Naleway AL, Irving SA, DeSilva MB, Kharbanda AB, Ong TC, Rao S, Zheng K, Gohil SK, Ball SW, Fink RV, Reed C, Garg S, Bozio CH. Influenza-Associated Hospitalization Rates by Underlying Conditions, 2016-2017 to 2019-2020: A Retrospective Cohort Study. J Infect Dis. 2025 Oct 15; 232(4):e642-e650.
Score: 0.041
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|